Similar articles

• Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products.

  Nagy L, Lee TH, Goetzl EJ, Pickett WC, Kay AB. Nagy L, et al. Clin Exp Immunol. 1982 Mar;47(3):541-7. Clin Exp Immunol. 1982. PMID: 6282507 Free PMC article.
• Potentiating actions of hydroxyeicosatetraenoates on human neutrophil degranulation responses to leukotriene B4 and phorbol myristate acetate.

  O'Flaherty JT, Thomas MJ, McCall CE, Wykle RL. O'Flaherty JT, et al. Res Commun Chem Pathol Pharmacol. 1983 Jun;40(3):475-87. Res Commun Chem Pathol Pharmacol. 1983. PMID: 6312514
• Enhancement of neutrophil- and eosinophil-mediated complement-dependent killing of schistosomula of Schistosoma mansoni in vitro by leukotriene B4.

  Moqbel R, Sass-Kuhn SP, Goetzl EJ, Kay AB. Moqbel R, et al. Clin Exp Immunol. 1983 Jun;52(3):519-27. Clin Exp Immunol. 1983. PMID: 6307558 Free PMC article.
• [Pharmacology of the leukotrienes].

  Sirois P, Borgeat P. Sirois P, et al. J Pharmacol. 1984;15 Suppl 1:53-68. J Pharmacol. 1984. PMID: 6328128 Review. French.
• Leukotrienes: mediators of inflammation and immediate hypersensitivity reactions.

  Malmsten CL. Malmsten CL. Crit Rev Immunol. 1984;4(4):307-34. Crit Rev Immunol. 1984. PMID: 6325090 Review. No abstract available.